Fulvestrant Drug Classification
Fulvestrant belongs to the class of selective estrogen receptor degraders (SERDs), also classified as a pure antiestrogen or estrogen receptor (ER) antagonist. 1, 2, 1
Mechanism of Action
Fulvestrant functions through a unique mechanism that distinguishes it from other endocrine agents:
- Binds to estrogen receptors with high affinity
- Blocks estrogen receptor activity completely
- Degrades/downregulates the estrogen receptor in a dose-dependent manner (approximately 70% reduction at 250 mg dose, approaching 100% at higher doses) 3
- Lacks estrogen agonistic activity unlike tamoxifen, making it a "pure" antiestrogen 1
Classification Context
The NCCN guidelines 1 categorize endocrine therapies for postmenopausal women into distinct drug classes:
- Selective, nonsteroidal aromatase inhibitors (anastrozole, letrozole)
- Steroidal aromatase inhibitors (exemestane)
- Pure antiestrogens (fulvestrant) - this is where fulvestrant is explicitly classified
- Progestins (megestrol acetate)
- Androgens (fluoxymesterone)
- High-dose estrogens (ethinyl estradiol)
Clinical Formulation
Fulvestrant is administered as an intramuscular injection 4:
- Standard dose: 500 mg monthly (given as two 250 mg/5 mL injections)
- Loading dose regimen: 500 mg on day 0, day 14, day 28, then monthly
- Must be refrigerated and protected from light 4
Important Distinction
While tamoxifen is a selective estrogen receptor modulator (SERM) with both agonist and antagonist properties depending on tissue type, fulvestrant is a selective estrogen receptor degrader (SERD) with pure antagonist activity and no agonist effects 2, 5, 6. This fundamental difference in mechanism explains why fulvestrant remains effective in patients who have progressed on tamoxifen or aromatase inhibitors.